Visceral Fat: An Underestimated Health Risk
For decades, medicine has focused on weight and the Body Mass Index (BMI). But these numbers only tell half the story. You can have a "normal" BMI and still carry an elevated metabolic risk. A…
For decades, medicine has focused on weight and the Body Mass Index (BMI). But these numbers only tell half the story. You can have a "normal" BMI and still carry an elevated metabolic risk. A crucial, yet often invisible factor behind this is visceral fat.
This is the fat you cannot pinch. It wraps deep inside your abdominal cavity around your liver, intestines, and pancreas. For decades, researchers considered this tissue a passive storage depot. However, since the 1990s, studies have shown that it produces hormones and inflammatory messengers. This discovery moved it to the center of diabetes and cardiovascular research.
This article explains why understanding visceral fat health risks is so relevant, how the tissue can be assessed and measured, and which evidence-based strategies may help reduce it.
What Is Visceral Fat?
Visceral fat, also known as intra-abdominal fat, lies deep within your abdominal cavity and surrounds organs such as the liver and intestines. It is hormonally and immunologically active: the tissue produces inflammatory substances and influences your metabolic risk.
The body stores fat in two very different locations. For your health, this distinction matters significantly:
- Subcutaneous fat: This fat lies directly under the skin. You can pinch it on your abdomen, thighs, or buttocks. It serves as an energy reserve and insulation layer. While an excess can also be problematic, subcutaneous fat is considered less critical metabolically.
- Visceral fat: This fat is located in the abdominal cavity and envelops your internal organs. Blood from parts of this adipose tissue flows directly to the liver via the portal vein, which transports blood from the digestive tract. This anatomical connection is considered an important reason for its metabolic significance.
The main flaw of the BMI is that it differentiates neither between these types of fat nor between muscle and fat mass. A muscular athlete can have a high BMI and be healthy. Conversely, a slim person with little muscle but a lot of visceral fat can exhibit an elevated disease risk. Obesity research calls this phenomenon TOFI: "Thin Outside, Fat Inside."
From Passive Storage to Active Tissue: Understanding Visceral Fat Health Risks
The shift in our understanding of adipose tissue is among the most important medical insights of recent decades. Visceral fat functions as an endocrine organ. The tissue releases dozens of bioactive substances known as adipokines.
The Messengers of Visceral Fat
An excess of visceral fat can shift the balance of these messengers in an unfavorable direction:
- Pro-inflammatory cytokines: Visceral fat produces increased levels of inflammatory messengers such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). These can promote a state of chronic, low-grade inflammation ("silent inflammation"), which is considered a breeding ground for atherosclerosis and insulin resistance. The inflammatory marker hs-CRP (high-sensitivity C-reactive protein), which is measured in the YEARS Core® program, can reflect this inflammatory activity in the blood, though it is not specific to visceral fat.
- Elevated free fatty acids: Visceral fat cells readily release free fatty acids into the bloodstream. Via the portal vein, these travel directly to the liver, where they can disrupt glucose and lipid metabolism and contribute to the development of non-alcoholic fatty liver disease (NAFLD). (Medically, NAFLD is now increasingly referred to as MASLD.)
- Hormonal dysregulation: The effect of the satiety hormone leptin may be weakened (leptin resistance), which can contribute to persistent feelings of hunger. At the same time, the production of protective adiponectin—which improves insulin sensitivity and has anti-inflammatory effects—decreases.
This process contributes to the development of insulin resistance. The HOMA index, a marker in the YEARS Core® program, is calculated from fasting glucose and fasting insulin and can indicate an early stage of this metabolic disorder, often before fasting blood sugar rises in a standard test.
The Consequences: Diseases Associated with Visceral Fat
Chronic inflammation and metabolic dysfunction can lay the groundwork for a range of serious conditions:
| Risk Factor / Disease | Association with Visceral Fat |
|---|---|
| Metabolic Syndrome | Visceral fat is considered a central driver of this risk cluster, which includes high blood pressure, abnormal blood lipids, and high blood sugar. |
| Type 2 Diabetes | Visceral fat is associated with insulin resistance, a major precursor to type 2 diabetes, and is considered one of the important modifiable risk factors. |
| Cardiovascular Diseases | Associated with high blood pressure, unfavorable blood lipid levels (dyslipidemia, assessable via ApoB, among others), and an accelerated progression of atherosclerosis. |
| Non-Alcoholic Fatty Liver Disease (NAFLD) | The flooding of the liver with free fatty acids can lead to fat deposits, which may progress to inflammation (NASH) and cirrhosis. |
| Dementia & Cognitive Decline | Observational studies point to an association between visceral adiposity, chronic inflammation, insulin resistance, and an increased risk of dementia. The causal mechanisms are not yet fully understood. |
| Certain Cancers | Chronic inflammation and obesity are linked to an increased risk of colon and pancreatic cancer. |
How to Measure Visceral Fat: From Tape Measures to Imaging
Because visceral fat is an important risk factor, assessing it is a standard part of modern preventive medicine. The methods differ in their precision.
Method 1: Waist Circumference (At-Home Screening)
The simplest method is measuring your waist circumference. It is a good, albeit indirect, indicator.
- Instructions: Place a measuring tape horizontally around your abdomen, midway between your lowest rib and the top of your iliac crest (WHO protocol). Measure at the end of a normal exhalation without pulling your stomach in. Repeat the measurement on three consecutive days and calculate the average; individual values can vary by one to two centimeters depending on the time of day and digestion.
- Thresholds (WHO / IDF, Europid population):
| Elevated Risk | Severely Elevated Risk | |
|---|---|---|
| Men | ≥ 94 cm | ≥ 102 cm |
| Women | ≥ 80 cm | ≥ 88 cm |
Method 2: Body Composition Analysis (BIA & 3D Body Scan)
Modern analytical tools provide more nuanced insights than a tape measure. As part of the YEARS Core® program, we utilize:
- Bioelectrical Impedance Analysis (BIA): A weak electrical current measures the proportions of fat, muscle, and water in the body. Professional devices provide an estimate of the visceral fat percentage, though their accuracy is limited compared to cross-sectional imaging.
- 3D Body Scan: Creates a digital map of your body and calculates detailed circumference and volume measurements, which can objectively visualize changes over time.
Method 3: Imaging Techniques (Reference Standard)
The most exact quantification of visceral fat is achieved through cross-sectional imaging.
- DXA Scan: Originally developed for bone density measurement, DXA technology provides a breakdown of fat, muscle, and bone mass, as well as an estimate of visceral fat.
- Magnetic Resonance Imaging (MRI) and Computed Tomography (CT): These are considered the reference standard. An MRI creates radiation-free cross-sectional images of the abdomen, allowing visceral fat to be distinguished from subcutaneous fat and its volume calculated. The whole-body MRI is a component of the YEARS Evolve® program (not the Core® program) and can make structural abnormalities visible.
What You Can Do: Evidence-Based Strategies to Reduce Visceral Fat
Visceral fat often responds more quickly to lifestyle changes than stubborn subcutaneous fat.
1. Dietary Adjustments
A sustainable adjustment works better here than a radical diet. The goal is fewer insulin spikes and less inflammation.
- Reduce sugar and refined carbohydrates: Sugar, white flour products, and sweetened beverages may promote fat storage in the visceral area.
- Focus on fiber and proteins: Soluble fiber (oats, legumes) and high-quality proteins keep you full longer and can stabilize blood sugar. A guideline is 25 to 30 grams of fiber per day. This equates to about 60 g of oatmeal for breakfast, a bowl of lentil soup for lunch, and two apples spread throughout the day.
- Prefer unsaturated fats: Omega-3 fatty acids from fatty fish, flaxseeds, and walnuts have anti-inflammatory effects.
- Limit alcohol: High alcohol consumption can inhibit fat breakdown and may promote fat accumulation in the liver.
2. Targeted Exercise
Studies associate the combination of endurance and strength training with the greatest reduction in visceral fat.
- Endurance training (Cardio): Moderate to vigorous exercise (running, cycling) increases energy expenditure. The WHO recommends 150 to 300 minutes of moderate activity per week, spread over three to five sessions. High-intensity interval training (HIIT) appears to be particularly effective, though the study data is not entirely uniform.
- Strength training: More muscle mass can improve insulin sensitivity and increases your basal metabolic rate. This means the body burns slightly more energy even at rest.
3. Sleep and Stress Management
Chronic sleep deprivation (< 7 hours) and persistent stress are associated with elevated cortisol levels and increased fat storage in the abdominal area. Techniques such as meditation, yoga, or regular movement in nature can contribute to stress reduction and thus potentially to more favorable cortisol levels.
How YEARS Assesses Your Metabolic Risk
If you want to know your own risk, you need numbers. At YEARS, we compile a data-driven, comprehensive picture of your metabolic health.
In the YEARS Core® program, we combine several diagnostic pillars:
- Body composition: Bioelectrical Impedance Analysis (BIA) and a 3D body scan assess your body fat percentage and circumference measurements.
- Metabolic biomarkers: The HOMA index can provide indications of early insulin resistance. ApoB is a more precise risk marker for cardiovascular risk than classic LDL.
- Inflammatory markers: High-sensitivity C-reactive protein (hs-CRP) indicates the level of systemic inflammation.
- Organ imaging: An advanced ultrasound of the abdominal organs can provide indications of a fatty liver. Additionally, liver values in the blood can be evaluated.
During the strategy consultation, about two weeks after your visit, the YEARS medical team synthesizes all this data and discusses all identified risks with you. This creates your individual risk profile and a concrete, prioritized plan.
If you want to know where you stand, measuring is the only alternative to guessing. Gain clarity about your individual metabolic risk.
Book your consultation now or discover the YEARS Core® program.
This article is for general informational purposes only and does not replace individual medical advice.
---
Sources
- FET e.V. Fachgesellschaft für Ernährungstherapie und Prävention. Das Fettgewebe – ein hochaktives (endokrines) Organ. Retrieved from fet-ev.de.
- Gamarra, P. F., D'Marco, L., et al. (2021). Visceral Adipose Tissue Is a Predictor of Recurrent Cardiovascular Events in Patients With Coronary Artery Disease. Journal of the American Heart Association (JAHA), 10(23), e022510. DOI: 10.1161/JAHA.121.022510.
- International Diabetes Federation (IDF). (2006). The IDF consensus worldwide definition of the metabolic syndrome. PDF.
- NDR Ratgeber. (2024). Bauchfett: Wie man das ungesunde viszerale Fett verliert. Retrieved from ndr.de.
- Wellen, K. E., & Hotamisligil, G. S. (2003). Obesity-induced inflammatory changes in adipose tissue. The Journal of Clinical Investigation (JCI), 112(12), 1785–1788. DOI: 10.1172/JCI20514.
- World Health Organization (WHO). (2011). Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation (Genf, 2008). Geneva. ISBN 978-92-4-150149-1.
Frequently asked questions on this topic
Can you target belly fat specifically?
Spot reduction of fat at a particular body site does not work. Abdominal exercises strengthen the muscle underneath, but they do not release fat from the abdominal cavity. The encouraging part is that visceral fat responds preferentially anyway: it is metabolically more active and better perfused than subcutaneous fat, and it often shrinks faster under an energy deficit than fat on hips and thighs. In studies, the visceral compartment decreases disproportionately during weight loss. What works is therefore the combination of a moderate calorie reduction, regular endurance and strength training, sufficient sleep and little alcohol. Reducing belly fat measurably is a matter of changing the overall balance of nutrition, movement and recovery, not the exercise selection.
How long does it take for visceral fat to decrease measurably?
In intervention studies, first measurable changes typically appear after eight to twelve weeks of consistent adjustment. Waist circumference responds earlier than body weight, because visceral fat is mobilised preferentially. A weight loss of just five to ten percent already improves blood pressure, triglycerides, insulin sensitivity and liver fat substantially, even when little is visible yet. It is important not to judge progress by the scale alone. Anyone doing strength training builds muscle at the same time, so weight appears to stall while body composition improves. Waist circumference, bioelectrical impedance under identical conditions, and metabolic markers such as HOMA-IR, triglycerides and hs-CRP track the development more reliably. Progress is rarely linear either: a fast start is often followed by weeks of little visible movement.
My waist circumference is normal. Can I still carry a lot of visceral fat?
Yes. Waist circumference is a good screening tool, but it cannot distinguish subcutaneous from visceral fat. Two people with an identical measurement can carry very different amounts internally. This matters particularly in lean individuals with little muscle mass, described in research as TOFI. The established thresholds also come predominantly from European populations; lower cut-offs apply for South and East Asian ancestry. Signals of a hidden problem include elevated triglycerides with low HDL, a raised HOMA-IR, abnormal liver values, or fatty liver visible on ultrasound. Knowing for certain requires a body composition measurement, and in case of doubt, imaging. The reverse also holds: a strong, muscular torso can raise the measurement without much fat sitting inside.
Do GLP-1 medications such as semaglutide reduce visceral fat?
Yes. In studies, GLP-1 receptor agonists reduce visceral fat alongside total weight, in some analyses disproportionately, while blood glucose, blood pressure and inflammatory markers improve. Two caveats belong with that. First, muscle mass is lost along with fat, in analyses a considerable share of total loss, which makes strength training and adequate protein important during therapy. Second, weight largely returns after discontinuation in many people if the lifestyle foundation is missing. These medications are prescription-only and tied to medical criteria; they are not a shortcut available to everyone. Whether treatment makes sense belongs in a medical assessment that looks at the entire risk profile. As an addition to diet and training they can achieve a great deal, as a replacement for them rather little.
Why does visceral fat increase in women after menopause?
Before menopause, oestrogen shifts fat storage towards hips and thighs. As oestrogen levels fall, distribution moves towards the abdominal cavity, even without weight gain. Studies show a marked rise in the visceral compartment across the transition, accompanied by less favourable blood lipids, rising blood pressure and declining insulin sensitivity. This helps explain why cardiovascular risk in women increases noticeably during this stage of life. In practice, strength training and protein intake become more important, because muscle mass is being lost in parallel, and metabolic markers deserve regular monitoring in this phase. Whether hormone therapy is an option is an individual medical decision with its own benefits and drawbacks.
Related pages at YEARS
- Blood Values & Biomarkers in a Check-upThe complete panel register, every marker listed.
- Detecting Hashimoto's EarlyTSH, antibodies, ultrasound and monitoring, with our co-founder's own case.
- VO2max Test BerlinSpiroergometry instead of a wearable estimate.
- Biological AgeWhat is behind the number and what it does not say.
